CancerGIFTTNCT07517666
Genetic Information for Families After Tumor Testing Study
A study testing Interactive Chatbot in people with Cancer, run by Abramson Cancer Center at Penn Medicine at 1 site in United States.
Trial summary
The purpose of this study is to develop and implement a methodology of digital tools paired with telemedicine to improve cascade testing for clinically significant germline mutations among family members of children with cancer who have a pathogenic or likely pathogenic(P/LP) germline variant in a cancer… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cancer
- What is being tested?
- Interactive Chatbot
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Jul 2026to Mar 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Biological parent of a child enrolled in the ORIGen cohort (AEPI24N1) who has a confirmed P/LP germline variant in a CPG.
- 18 years of age or older.
- Speak and understand English.
Who cannot join
- Previous genetic testing for the familial variant.
- Communication difficulties such as:
- Uncorrected or uncompensated hearing and/or vision impairment. Patients who can successfully use clinical assistance devices are not excluded.
- Uncorrected or uncompensated speech defects. Patients who can successfully use clinical assistance devices are not excluded.
- Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
About this study
Official title: Genetic Information for Families After Tumor Testing (GIFTT) Study
The purpose of this study is to develop and implement a methodology of digital tools paired with telemedicine to improve cascade testing for clinically significant germline mutations among family members of children with cancer who have a pathogenic or likely pathogenic(P/LP) germline variant in a cancer predisposition gene.
- Conditions
- Cancer
- Being tested
- Interactive Chatbot
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Interactive ChatbotOther
The chatbot intervention will provide biological parents the option to complete pre-test education using an interactive chatbot as an alternative to remote counseling with a genetic counselor. This interactive chatbot will provide opportunities for longitudinal educational and information support, reminders for scheduling next steps, and the option to send specific questions to the genetic counseling team.
| Study group | Role | What they receive |
|---|---|---|
| Single Arm | Experimental | Genetic counseling via digital tools and telemedicine Receives: Other: Interactive Chatbot |
What is being measured
The primary outcome is the main question the study is designed to answer.
Uptake of digital pre-test chatbot
Participant completion of digital intervention as an alternative for pre-test counseling (yes/no)
Measured: 6 months from consent
Uptake of genetic testing
Participant completion of genetic testing (yes/no)
Measured: 6 months from consent
Secondary outcomes (6)
Understanding of Genetic Information
Will be evaluated using an adapted version of the KnowGene Scale, a 16-item scale administered to patients after genetic testing and/or genetic counseling to measure their understanding of the health implications of genetic testing results
Measured: Change from Baseline to within 7 days post-education, and from baseline to 6 months after disclosure of genetic test results
General anxiety and Depression
Will be measured by the 4-item each short Patient Reported Outcomes Measurement Information System (PROMIS) measures
Measured: Change from baseline to within 7 days post-education, and from baseline to 6 months after disclosure of genetic test results
Reactions to genetic information
Will be measured using an 8-item Impact of Events Scale (IES)
Measured: Change from baseline to within 7 days post-education, and from baseline to 6 months after disclosure of genetic test results
Satisfaction with genetic services
Will be assessed with a 14-items evaluating satisfaction with genetic services
Measured: Within 7 days post-education, and within 7 days after disclosure of genetic test results
Psychosocial impact of returning genomic findings
Evaluation of distress, uncertainty and positive responses to receipt of genetic test results using 17 items from the MICRA (Multi-dimensional Impact of Cancer Risk Assessment Questionnaire)
Measured: Within 7 days after disclosure of genetic test results, and at 6 months after disclosure of genetic test results
Decisional regret
Evaluated using 5-item validated Decision Regret Scale
Measured: Within 7 days after disclosure of genetic test results, and at 6 months after disclosure of genetic test results
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2026
- Study start15 Jul 2026
- Primary completionMar 2028 (estimated)
- Study completionMar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by Abramson Cancer Center at Penn MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- Emory University, Baylor College of Medicine, Fox Chase Cancer Center, National Cancer Institute (NCI), Dana-Farber Cancer Institute, Ann & Robert H Lurie Children's Hospital of Chicago
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07517666
- Sponsor's protocol ID
- 05026
- Acronym
- GIFTT
- Status last verified
- Jul 2026
- First submitted
- 2 Apr 2026
- Last updated
- 29 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Genetic Information for Families After Tumor Testing (GIFTT) Study
- ClinicalTrials.gov ID
- NCT07517666
- Acronym / sponsor ID
- GIFTT / 05026
- Conditions
- Cancer
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Abramson Cancer Center at Penn MedicineUniversity, hospital or other
- Collaborators
- Emory University, Baylor College of Medicine, Fox Chase Cancer Center, National Cancer Institute (NCI), Dana-Farber Cancer Institute, Ann & Robert H Lurie Children's Hospital of Chicago
- Study start
- 15 Jul 2026 (actual)
- Primary completion
- Mar 2028 (estimated)
- Study completion
- Mar 2028 (estimated)
- First posted
- 8 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to develop and implement a methodology of digital tools paired with telemedicine to improve cascade testing for clinically significant germline mutations among family members of children with cancer who have a pathogenic or likely pathogenic(P/LP) germline variant in a cancer predisposition gene.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Single Arm | Experimental | Other: Interactive ChatbotGenetic counseling via digital tools and telemedicine |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Biological parent of a child enrolled in the ORIGen cohort (AEPI24N1) who has a confirmed P/LP germline variant in a CPG.
- 18 years of age or older.
- Speak and understand English.
Key exclusion criteria (5 listed)
- Previous genetic testing for the familial variant.
- Communication difficulties such as:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Interactive ChatbotThe chatbot intervention will provide biological parents the option to complete pre-test education using an interactive chatbot as an alternative to remote counseling with a genetic counselor. This interactive chatbot will provide opportunities for longitudinal educational and information support, reminders for scheduling next steps, and the option to send specific questions to the genetic counseling team. | Other | Single Arm |
Primary outcome
Uptake of digital pre-test chatbot
Time frame: 6 months from consent
Participant completion of digital intervention as an alternative for pre-test counseling (yes/no)
Uptake of genetic testing
Time frame: 6 months from consent
Participant completion of genetic testing (yes/no)
6 secondary outcomes
Understanding of Genetic Information
Time frame: Change from Baseline to within 7 days post-education, and from baseline to 6 months after disclosure of genetic test results
General anxiety and Depression
Time frame: Change from baseline to within 7 days post-education, and from baseline to 6 months after disclosure of genetic test results
Reactions to genetic information
Time frame: Change from baseline to within 7 days post-education, and from baseline to 6 months after disclosure of genetic test results
Satisfaction with genetic services
Time frame: Within 7 days post-education, and within 7 days after disclosure of genetic test results
Psychosocial impact of returning genomic findings
Time frame: Within 7 days after disclosure of genetic test results, and at 6 months after disclosure of genetic test results
Decisional regret
Time frame: Within 7 days after disclosure of genetic test results, and at 6 months after disclosure of genetic test results
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Cancer
Enrolling by invitation
Exercise Intervention for Breast Cancer Patients With Sarcopenia
Sarcopenia, Breast Cancer
RecruitingPhase 3
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
IO Resistant Squamous and Nonsquamous NSCLC
Not yet recruitingPhase 2
Saruparib in HRDsig+ Solid Tumors
Malignant Neoplastic Disease (Disorder)
RecruitingPhase 2
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
Fallopian Tube Carcinoma, Ovarian Carcinoma
Not yet recruitingPhase 2
Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Interactive Chatbot in people with Cancer, run by Abramson Cancer Center at Penn Medicine at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 29 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Uptake of digital pre-test chatbot (time frame: 6 months from consent). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2026.